Li, D. et al. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Metab. https://doi.org/10.1016/j.diabet.2018.02.001 (2018).
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644-657 (2017).
Khouri, C., Cracowski, J. L. & Roustit, M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes. Metab. https://doi.org/10.1111/dom.13255 (2018).
Inzucchi, S. E. et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41, e4-e5 (2018).
Monami, M. et al. Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol. 54, 411-413 (2017).
Kohler, S. et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv. Ther. 34, 1707-1726 (2017).
Jabbour, S. et al. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes. Metab. 20, 620-628 (2018).
Udell, J. A. et al. Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL population-based cohort study. Circulation https://doi.org/10.1161/CIRCULATIONAHA.117.031227 (2017).
Yuan, Z. et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes. Metab. 20, 582-589 (2018).
Fadini, G. & Avogaro, A. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 5, 680-681 (2017).
